Agennix Receives U.S. Patent On Production of Recombinant Lactoferrin.HOUSTON--(BW HealthWire)--July 13, 1998--Agennix Incorporated today announced that it has been granted a patent from the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property (no. 5,766,939) for the production of recombinant lactoferrin lactoferrin (lak´tōfer´in), n an iron-binding protein found in the specific granules of neutrophils where it apparently exerts an antimicrobial activity by withholding iron from ingested bacteria and fungi. . The patent specifically covers production of recombinant human lactoferrin and lactoferrin polypeptides including functional polypeptides in various organisms. Lactoferrin is a natural antimicrobial protein. Agennix is in early phase clinical development for lactoferrin-based products for a variety of inflammatory indications, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Denis Denis, king of Portugal: see Diniz. R. Headon, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "This patent, in addition to the three which were issued in November 1996, represent a strong patent portfolio for our core technology," Headon said. "Our patented technology allows us to advance the research and development of a new class of anti-inflammatory drugs Anti-inflammatory drugs A class of drugs that lower inflammation and that includes NSAIDs and corticosteroids. Mentioned in: Antirheumatic Drugs , which are currently in various clinical development studies for the treatment of inflammatory conditions. We have a manufacturing agreement with Royal Gist-Brocades N.V. of the Netherlands." Agennix's patent estate now includes U.S. patents covering cDNA sequences encoding human lactoferrin, methods for producing recombinant human lactoferrin from a variety of host cell systems, and the production of lactoferrin polypeptides, in addition to numerous patents covering applications of lactoferrin. Agennix, Inc. is a Houston, Texas “Houston” redirects here. For other uses, see Houston (disambiguation). Houston (pronounced /'hjuːstən/) is the largest city in the state of Texas and the based biotechnology company engaged in the research and development of a new class of natural anti-inflammatory/anti-infective agents. The Company's core underlying technology is built on human lactoferrin, an anti-inflammatory and immunomodulatory protein with applications in the treatment of inflammatory and infectious diseases.
CONTACT: Agennix, Inc.
Denis R. Headon, Ph.D., 713/796-1091
Email: agennix@agennix.com
or
Mentus, Inc.
Linda Seaton, 619/455-5500 ext. 133
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion